

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**FOSUN 复星**

**復星國際有限公司**  
**FOSUN INTERNATIONAL LIMITED**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 00656)**

**CHANGE OF DIRECTORS AND COMPANY EXECUTIVES  
AND  
CHANGE OF THE COMPOSITION OF  
BOARD COMMITTEES**

The Board announces the following change of directors and company executives and change of the composition of Board committees of the Company:

1. Mr. Liang Xinjun has resigned as an executive director, vice chairman, chief executive officer and the member of the remuneration committee of the Company with effect from 28 March 2017;
2. Mr. Ding Guoqi has resigned as an executive director and senior vice president of the Company with effect from 28 March 2017;
3. Mr. Wang Qunbin, an executive director of the Company, has been re-designated as the chief executive officer and appointed as a member of the remuneration committee of the Company with effect from 28 March 2017;
4. Mr. Chen Qiyu, an executive director of the Company, has been appointed as the co-president of the Company with effect from 28 March 2017;
5. Mr. Xu Xiaoliang, an executive director of the Company, has been appointed as the co-president of the Company with effect from 28 March 2017;
6. Mr. Wang Can has been appointed as an executive director and senior vice president of the Company with effect from 28 March 2017;
7. Ms. Kang Lan has been appointed as an executive director and senior vice president of the Company with effect from 28 March 2017;
8. Mr. Gong Ping has been appointed as an executive director and senior vice president of the Company with effect from 28 March 2017; and
9. Dr. Lee Kai-Fu has been appointed as an independent non-executive director and a member of each of the audit committee, remuneration committee and nomination committee of the Company with effect from 28 March 2017.

The board of directors (the “**Board**”) of Fosun International Limited (the “**Company**”) announces the following change of directors and company executives and change of the composition of Board committees of the Company:

1. Mr. Liang Xinjun (“**Mr. Liang**”) has resigned as an executive director, vice chairman, chief executive officer and the member of the remuneration committee of the Company with effect from 28 March 2017;
2. Mr. Ding Guoqi (“**Mr. Ding**”) has resigned as an executive director and senior vice president of the Company with effect from 28 March 2017;
3. Mr. Wang Qunbin, an executive director of the Company, has been re-designated as the chief executive officer and appointed as a member of the remuneration committee of the Company with effect from 28 March 2017;
4. Mr. Chen Qiyu, an executive director of the Company, has been appointed as the co-president of the Company with effect from 28 March 2017;
5. Mr. Xu Xiaoliang, an executive director of the Company, has been appointed as the co-president of the Company with effect from 28 March 2017;
6. Mr. Wang Can (“**Mr. Wang**”) has been appointed as an executive director and senior vice president of the Company with effect from 28 March 2017;
7. Ms. Kang Lan (“**Ms. Kang**”) has been appointed as an executive director and senior vice president of the Company with effect from 28 March 2017;
8. Mr. Gong Ping (“**Mr. Gong**”) has been appointed as an executive director and senior vice president of the Company with effect from 28 March 2017; and
9. Dr. Lee Kai-Fu (“**Dr. Lee**”) has been appointed as an independent non-executive director and a member of each of the audit committee, remuneration committee and nomination committee of the Company with effect from 28 March 2017.

### **Resignation of Mr. Liang and Mr. Ding**

Mr. Liang has resigned as an executive director, vice chairman, chief executive officer and the member of the remuneration committee of the Company with effect from 28 March 2017 due to health reasons; and Mr. Ding has resigned as an executive director and senior vice president of the Company with effect from 28 March 2017 for devoting more time to family commitments.

Both Mr. Liang and Mr. Ding have confirmed that they have no disagreement with the Board and there is nothing relating to their resignations that needs to be brought to the attention of the shareholders of the Company. Mr. Liang and Mr. Ding will not hold any position in the Company after their resignations.

The Board would like to express its sincere gratitude to both Mr. Liang and Mr. Ding for their valuable efforts and contributions to the Company during their term of office with the Company.

### **Details of the newly appointed directors**

#### ***Mr. Wang***

Mr. Wang, aged 37, is an executive director, senior vice president and the chief financial officer (the “**CFO**”) of the Company. Mr. Wang joined the Company and its subsidiaries (the “**Group**”) in 2012, and is now the general manager of the chairman and president office and the investment management center. He is a non-executive director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (listed on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) with stock code: 02196 and Shanghai Stock Exchange with stock code: 600196) (“**Fosun Pharma**”), and director of other companies within the Group. He was previously the general manager of the investment management department, deputy CFO and general manager of the financial planning & analysis department of the Group. Prior to joining the Group, Mr. Wang worked in Kingdee Software (China) Co., Ltd., PricewaterhouseCoopers Zhong Tian LLP, Standard Chartered Bank (China) Limited and China Lodging Group Limited (NASDAQ: HTHT). Mr. Wang is a non-practicing member of Chinese Institute of Certified Public Accountants (CICPA) and a member of the Association of International Accountants (AIA). Mr. Wang graduated from Anhui University in 1997 and received an executive master of business administration (EMBA) degree from China Europe International Business School in 2014.

As at the date of this announcement, Mr. Wang is deemed to hold 4,225,000 shares of the Company.

Save as disclosed above, Mr. Wang does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed above, as at the date of this announcement, Mr. Wang (i) does not hold any significant position in the Company or other members of the Group; (ii) does not have any relationships with any other directors, senior management or substantial or controlling shareholders of the Company; (iii) does not have, and/or is not deemed to have, any interest or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (iv) does not have other major appointments or professional qualifications.

Mr. Wang has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 28 March 2017, and is subject to retirement by

rotation and re-election at the annual general meeting of the Company in accordance with the Company's articles of association. Mr. Wang is entitled to a remuneration of RMB3,000,000 per annum which is determined by the Board taking reference to his duties and responsibilities and the Company's remuneration policy. He is also entitled to an annual discretionary bonus determined by the internal regulation of the Company.

There are no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Mr. Wang or is there any other information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited ("**Listing Rules**").

### ***Ms. Kang***

Ms. Kang, aged 48, is an executive director, senior vice president and chief human resources officer of the Company and a president of Fosun insurance group. Ms. Kang joined the Group in 2010, and is also a non-executive director of Fosun Pharma, chairman of Meadowbrook Insurance Group, Inc. and director of various insurance companies and other companies within the Group. Ms. Kang was a project manager of Nanjing High Technology Industry Development Company from August 1991 to June 1993, a researcher of Memorial Sloan-Kettering Cancer Center in the United States from October 1995 to May 1998, a research and development scientist in Wyeth from May 1998 to August 2000, a consultant of McKinsey & Company, Greater China Office from August 2002 to February 2007, and a senior client partner of Korn/Ferry International Consulting Ltd., Greater China Office from March 2007 to August 2010. Ms. Kang received her bachelor's degree in biological sciences and biotechnology from Zhejiang University in 1991, master's degree in biochemistry from Tulane University in the United States in 1995, and master of business administration ("**MBA**") degree from the Wharton School of the University of Pennsylvania in 2002.

As at the date of this announcement, Ms. Kang is deemed to hold 7,370,000 shares of the Company.

Save as disclosed above, Ms. Kang does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed above, as at the date of this announcement, Ms. Kang (i) does not hold any significant position in the Company or other members of the Group; (ii) does not have any relationships with any other directors, senior management or substantial or controlling shareholders of the Company; (iii) does not have, and/or is not deemed to have, any interest or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance,

Chapter 571 of the Laws of Hong Kong); and (iv) does not have other major appointments or professional qualifications.

Ms. Kang has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 28 March 2017, and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company's articles of association. Ms. Kang is entitled to a remuneration of RMB3,000,000 per annum which is determined by the Board taking reference to her duties and responsibilities and the Company's remuneration policy. She is also entitled to an annual discretionary bonus determined by the internal regulation of the Company.

There are no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Ms. Kang or is there any other information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of Listing Rules.

### ***Mr. Gong***

Mr. Gong, aged 42, joined the Group in 2011. Mr. Gong serves as an executive director and senior vice president of the Company, chief executive officer of Fosun Property Holdings and chairman of Shanghai Forte Land Co., Ltd.. Mr. Gong is also a vice chairman of Shanghai Yuyuan Tourist Mart Co., Ltd. (listed on the Shanghai Stock Exchange with stock code: 600655), non-executive director of Shanghai Zendai Property Limited (listed on the Hong Kong Stock Exchange with stock code: 00755), as well as director of other companies within the Group. He used to serve as a senior assistant to president of the Group, and general manager of corporate development department. Prior to joining the Group, Mr. Gong worked at the Pudong branch and the headquarters of Bank of Shanghai as well as the People's Republic of China headquarters of Standard Chartered Bank. Mr. Gong also served as a global strategist at the headquarters of Samsung Group in Korea, carrying out special assignments across various sectors including financial services, technology and real estate worldwide. Mr. Gong graduated from Fudan University in 1998 with a bachelor's degree in international finance, and then obtained his master's degree in finance from Fudan University in 2005. Mr. Gong also received his MBA degree from International Institute for Management Development (IMD) in Lausanne, Switzerland in 2008.

As at the date of this announcement, Mr. Gong is deemed to hold 4,170,000 shares of the Company.

Save as disclosed above, Mr. Gong does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed above, as at the date of this announcement, Mr. Gong (i) does not hold any significant

position in the Company or other members of the Group; (ii) does not have any relationships with any other directors, senior management or substantial or controlling shareholders of the Company; (iii) does not have, and/or is not deemed to have, any interest or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (iv) does not have other major appointments or professional qualifications.

Mr. Gong has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 28 March 2017, and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company's articles of association. Mr. Gong is entitled to a remuneration of RMB3,000,000 per annum which is determined by the Board taking reference to his duties and responsibilities and the Company's remuneration policy. He is also entitled to an annual discretionary bonus determined by the internal regulation of the Company.

There are no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Mr. Gong or is there any other information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of Listing Rules.

#### ***Dr. Lee***

Dr. Lee Kai-Fu, aged 55, is an independent non-executive director of the Company. He is the chairman of Sinovation Ventures (Beijing) Enterprise Management Co., Ltd. (listed on the National Equities Exchange and Quotations with stock code: 835966), a co-founder and the managing partner of Sinovation Ventures Development Funds, the chairman and chief executive officer of Innovation Works Limited, a non-executive director of Meitu, Inc. (listed on the Hong Kong Stock Exchange with stock code: 01357), an independent director of LightInTheBox Holding Co., Ltd (listed on New York Stock Exchange with stock code: LITB), an independent non-executive director of Shangri-La Asia Limited (listed on the Hong Kong Stock Exchange with stock code: 00069) and Hon Hai Precision Industry Co., Ltd. (listed on the Taiwan Stock Exchange with stock code: 2317). Dr. Lee has also been a director of various companies in the internet, artificial intelligence and other industries. From 1988 to 1990, Dr. Lee worked at Carnegie Mellon University, where he served as an assistant professor; between July 1990 and April 1996, Dr. Lee worked at Apple Inc. (listed on NASDAQ with stock code: AAPL), serving as a vice-president from December 1995; from July 1998 to July 2005, Dr. Lee was the vice president at Microsoft Corporation (listed on NASDAQ with stock code: MSFT); from July 2005 to September 2009, Dr. Lee was the president of Google China of Google Inc. (listed on NASDAQ with stock code: GOOGL), and he was responsible for launching the Google China R&D Center. Dr. Lee received his bachelor of arts degree and Ph.D. in computer science from Columbia University in May 1983 and Carnegie Mellon University in May 1988, respectively.

Save as disclosed above, Dr. Lee does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed above, as at the date of this announcement, Dr. Lee (i) does not hold any significant position in the Company or other members of the Group; (ii) does not have any relationships with any other directors, senior management or substantial or controlling shareholders of the Company; (iii) does not have, and/or is not deemed to have, any interest or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (iv) does not have other major appointments or professional qualifications. Dr. Lee has confirmed that he meets the independence criteria as set out in Rule 3.13 of Listing Rules.

Dr. Lee has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 28 March 2017, and is subject to retirement by rotation and re-election at the annual general meeting in accordance with the Company's articles of association. Dr. Lee is entitled to a remuneration of HK\$550,000 per annum which is determined by the Board taking reference to his duties and responsibilities and the Company's remuneration policy.

There are no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Dr. Lee or is there any other information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of Listing Rules.

The Board would like to take this opportunity to welcome Mr. Wang, Ms. Kang, Mr. Gong and Dr. Lee to join the Board.

By Order of the Board  
**Fosun International Limited**  
**Guo Guangchang**  
*Chairman*

28 March 2017

*As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetao, Mr. Wang Can, Ms. Kang Lan and Mr. Gong Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.*